|
【结 构 式】 
|
【分子编号】51006 【品名】methyl (2S)-2-[[(4-[4-[(2-[[(benzyloxy)carbonyl]amino]ethyl)amino]-4-oxobutoxy]-2,6-dimethylphenyl)sulfonyl]amino]-3-[[(1-[3-[(1-trityl-1H-imidazol-2-yl)amino]propyl]-1H-indazol-5-yl)carbonyl]amino]propanoate 【CA登记号】 |
【 分 子 式 】C59H63N9O9S 【 分 子 量 】1074.27048 【元素组成】C 65.97% H 5.91% N 11.73% O 13.4% S 2.98% |
合成路线1
该中间体在本合成路线中的序号：(XII)Amine (X) was coupled with carboxylic acid (XI) to afford the corresponding amide (XII) (1,2). Basic hydrolysis of the ester group of (XII) gave acid (XIII), and subsequent cleavage of the remaining protecting groups of (XIII) with trifluoroacetic acid in the presence of triethylsilane furnished (XIV).
| 【1】 Rajopadhye, M.; Harris, T.D.; Cheesman, E.H. (DuPont Pharmaceuticals Co.); Vitronectin receptor antagonist pharmaceuticals. WO 0035488 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (X) | 51004 | methyl (2S)-3-amino-2-[[(4-[4-[(2-[[(benzyloxy)carbonyl]amino]ethyl)amino]-4-oxobutoxy]-2,6-dimethylphenyl)sulfonyl]amino]propanoate | C26H36N4O8S | 详情 | 详情 | |
| (XI) | 51005 | 1-[3-[(1-trityl-1H-imidazol-2-yl)amino]propyl]-1H-indazole-5-carboxylic acid | C33H29N5O2 | 详情 | 详情 | |
| (XII) | 51006 | methyl (2S)-2-[[(4-[4-[(2-[[(benzyloxy)carbonyl]amino]ethyl)amino]-4-oxobutoxy]-2,6-dimethylphenyl)sulfonyl]amino]-3-[[(1-[3-[(1-trityl-1H-imidazol-2-yl)amino]propyl]-1H-indazol-5-yl)carbonyl]amino]propanoate | C59H63N9O9S | 详情 | 详情 | |
| (XIII) | 51007 | (2S)-2-[[(4-[4-[(2-[[(benzyloxy)carbonyl]amino]ethyl)amino]-4-oxobutoxy]-2,6-dimethylphenyl)sulfonyl]amino]-3-[[(1-[3-[(1-trityl-1H-imidazol-2-yl)amino]propyl]-1H-indazol-5-yl)carbonyl]amino]propionic acid | C58H61N9O9S | 详情 | 详情 | |
| (XIV) | 51008 | (2S)-2-[[(4-[4-[(2-aminoethyl)amino]-4-oxobutoxy]-2,6-dimethylphenyl)sulfonyl]amino]-3-[([1-[3-(1H-imidazol-2-ylamino)propyl]-1H-indazol-5-yl]carbonyl)amino]propionic acid | C31H41N9O7S | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(XII)In a related procedure, intermediate (XII) was first deprotected by hydrogenolysis of the N-benzyloxycarbonyl group, yielding amine (XXV). Coupling of this amine with the dipeptide (XVII) furnished adduct (XXVI), which was again deprotected by hydrogenolysis, yielding (XXVII).
| 【1】 Cheesman, E.H.; et al.; Nonpeptide vitronectin antagonists labeles with in-111 for imaging tumors. 222nd ACS Natl Meet (Aug 26 2001, Chicago) 2001, Abst MEDI 88. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XII) | 51006 | methyl (2S)-2-[[(4-[4-[(2-[[(benzyloxy)carbonyl]amino]ethyl)amino]-4-oxobutoxy]-2,6-dimethylphenyl)sulfonyl]amino]-3-[[(1-[3-[(1-trityl-1H-imidazol-2-yl)amino]propyl]-1H-indazol-5-yl)carbonyl]amino]propanoate | C59H63N9O9S | 详情 | 详情 | |
| (XVII) | 51011 | (2S)-2-[[(2S)-2-[[(benzyloxy)carbonyl]amino]-5-(tert-butoxy)-5-oxopentanoyl]amino]-5-(tert-butoxy)-5-oxopentanoic acid | C26H38N2O9 | 详情 | 详情 | |
| (XXV) | 51017 | methyl (2S)-2-[[(4-[4-[(2-aminoethyl)amino]-4-oxobutoxy]-2,6-dimethylphenyl)sulfonyl]amino]-3-[[(1-[3-[(1-trityl-1H-imidazol-2-yl)amino]propyl]-1H-indazol-5-yl)carbonyl]amino]propanoate | C51H57N9O7S | 详情 | 详情 | |
| (XXVI) | 51018 | tert-butyl (4S)-4-[[(benzyloxy)carbonyl]amino]-5-[[(1S)-4-(tert-butoxy)-1-([[2-([4-[4-([[(1S)-2-methoxy-2-oxo-1-([[(1-[3-[(1-trityl-1H-imidazol-2-yl)amino]propyl]-1H-indazol-5-yl)carbonyl]amino]methyl)ethyl]amino]sulfonyl)-3,5-dimethylphenoxy]butanoyl]amino)ethyl]amino]carbonyl)-4-oxobutyl]amino]-5-oxopentanoate | C77H93N11O15S | 详情 | 详情 | |
| (XXVII) | 51019 | tert-butyl (4S)-4-amino-5-[[(1S)-4-(tert-butoxy)-1-([[2-([4-[4-([[(1S)-2-methoxy-2-oxo-1-([[(1-[3-[(1-trityl-1H-imidazol-2-yl)amino]propyl]-1H-indazol-5-yl)carbonyl]amino]methyl)ethyl]amino]sulfonyl)-3,5-dimethylphenoxy]butanoyl]amino)ethyl]amino]carbonyl)-4-oxobutyl]amino]-5-oxopentanoate | C69H87N11O13S | 详情 | 详情 |